$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

$acad Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000095017022021438 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$136.5M	$130.7M	$131.6M
YoY Change	4.38%	-0.68%	9.15%
Cost Of Revenue	$2.413M	$2.136M	$6.682M
YoY Change	-5.78%	-68.03%	39.21%
Gross Profit	$134.1M	$128.6M	$127.9M
YoY Change	4.49%	0.51%	7.89%
Gross Profit Margin	98.23%	98.37%	97.2%
Selling, General & Admin	$104.4M	$78.11M	$81.67M
YoY Change	-1.43%	-4.36%	0.08%
% of Gross Profit	77.87%	60.75%	63.84%
Research & Development	$75.74M	$81.34M	$58.57M
YoY Change	13.14%	38.88%	-51.24%
% of Gross Profit	56.49%	63.26%	45.78%
Depreciation & Amortization	$489.0K	$506.0K	$985.0K
YoY Change	-8.6%	-48.63%	38.73%
% of Gross Profit	0.36%	0.39%	0.77%
Operating Expenses	$180.1M	$159.4M	$140.2M
YoY Change	4.22%	13.7%	-30.48%
Operating Profit	-$46.06M	-$30.87M	-$12.31M
YoY Change	3.42%	150.8%	-85.2%
Interest Expense	$3.630M	$2.295M	$129.0K
YoY Change	2713.95%	1679.07%	-89.25%
% of Operating Profit
Other Income/Expense, Net	$1.543M	$2.156M	$383.0K
YoY Change	-4.93%	462.92%	-291.5%
Pretax Income	-$40.89M	-$26.42M	-$14.79M
YoY Change	-4.7%	78.61%	-82.58%
Income Tax	$835.0K	$768.0K	-$332.0K
% Of Pretax Income
Net Earnings	-$41.73M	-$27.18M	-$14.46M
YoY Change	-3.18%	88.03%	-82.92%
Net Earnings / Revenue	-30.57%	-20.8%	-10.98%
Basic Earnings Per Share	-$0.26	-$0.17	-$0.09
Diluted Earnings Per Share	-$0.26	-$0.17	-$89.98K
COMMON SHARES
Basic Shares Outstanding	161.9M	161.8M	160.7K
Diluted Shares Outstanding		161.9K	160.7K

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$416.8M	$436.6M	$540.3M
YoY Change	-19.95%	-19.2%	-16.16%
Cash & Equivalents	$114.8M	$154.8M	$100.4M
Short-Term Investments	$302.0M	$281.7M	$445.7M
Other Short-Term Assets	$21.40M	$22.99M	$24.62M
YoY Change	-10.44%	-6.62%	-17.93%
Inventory	$11.56M	$11.84M	$14.34M
Prepaid Expenses	$21.40M	$22.99M
Receivables	$62.20M	$55.73M	$60.70M
Other Receivables	$885.0K	$403.0K	$972.0K
Total Short-Term Assets	$507.9M	$521.6M	$640.9M
YoY Change	-17.79%	-18.62%	-12.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.021M	$6.510M	$68.61M
YoY Change	-25.18%	-90.51%	21.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.587M	$6.043M	$2.373M
YoY Change	89.82%	154.66%	-67.49%
Total Long-Term Assets	$79.88M	$80.94M	$76.76M
YoY Change	-2.95%	5.45%	17.18%
TOTAL ASSETS
Total Short-Term Assets	$507.9M	$521.6M	$640.9M
Total Long-Term Assets	$79.88M	$80.94M	$76.76M
Total Assets	$587.8M	$602.5M	$717.7M
YoY Change	-16.04%	-16.05%	-9.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.75M	$10.01M	$7.722M
YoY Change	85.37%	29.6%	120.63%
Accrued Expenses	$112.9M	$106.6M	$80.50M
YoY Change	26.56%	32.38%	-8.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$125.6M	$116.6M	$88.22M
YoY Change	30.77%	32.14%	-4.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$9.074M	$6.466M	$62.50M
YoY Change	29.0%	-89.65%	27.81%
Total Long-Term Liabilities	$9.074M	$6.466M	$62.50M
YoY Change	29.0%	-89.65%	27.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.6M	$116.6M	$88.22M
Total Long-Term Liabilities	$9.074M	$6.466M	$62.50M
Total Liabilities	$187.4M	$176.8M	$150.7M
YoY Change	17.69%	17.31%	7.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.370B	-$2.328B
YoY Change	10.03%
Common Stock	$2.771B	$2.755B
YoY Change	2.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$400.4M	$425.7M	$567.0M
YoY Change
Total Liabilities & Shareholders Equity	$587.8M	$602.5M	$717.7M
YoY Change	-16.04%	-16.05%	-9.81%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$41.73M	-$27.18M	-$14.46M
YoY Change	-3.18%	88.03%	-82.92%
Depreciation, Depletion And Amortization	$489.0K	$506.0K	$985.0K
YoY Change	-8.6%	-48.63%	38.73%
Cash From Operating Activities	-$23.85M	-$727.0K	-$17.06M
YoY Change	3.17%	-95.74%	-25.13%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$17.75M	$15.44M	-$156.3M
YoY Change	-124.81%	-109.88%	-201.03%
Cash From Investing Activities	-$17.75M	$15.44M	-$156.3M
YoY Change	-124.81%	-109.88%	-202.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.614M	287.0K	1.066M
YoY Change	-63.02%	-73.08%	-90.9%
NET CHANGE
Cash From Operating Activities	-23.85M	-727.0K	-17.06M
Cash From Investing Activities	-17.75M	15.44M	-156.3M
Cash From Financing Activities	1.614M	287.0K	1.066M
Net Change In Cash	-39.99M	15.00M	-172.3M
YoY Change	-175.74%	-108.71%	-221.42%
FREE CASH FLOW
Cash From Operating Activities	-$23.85M	-$727.0K	-$17.06M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$23.85M	-$727.0K	-$17.06M
YoY Change	3.18%	-95.74%	-19.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	403000
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	978000
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	us-gaap	Profit Loss ProfitLoss	-174250000
	us-gaap	Profit Loss ProfitLoss	-124776000
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
	dei	Entity Central Index Key EntityCentralIndexKey	0001070494
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2022Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-50768
	dei	Entity Registrant Name EntityRegistrantName	ACADIA PHARMACEUTICALS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1376651
	dei	Entity Address Address Line1 EntityAddressAddressLine1	12830 El Camino Real, Suite 400
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	558-2871
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	ACAD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	161930994
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154842000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	281737000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	373271000
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55733000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	64366000
CY2022Q3	acad	Short Term Inventory ShortTermInventory	5844000
CY2021Q4	acad	Short Term Inventory ShortTermInventory	7881000
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	22993000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23892000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	521552000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	617823000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6510000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56624000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58268000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2022Q3	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	5992000
CY2021Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	6217000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6043000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3997000
CY2022Q3	us-gaap	Assets Assets	602491000
CY2021Q4	us-gaap	Assets Assets	700122000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10008000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6876000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	106562000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89192000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	116570000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	96068000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53769000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56126000
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6466000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7034000
CY2022Q3	us-gaap	Liabilities Liabilities	176805000
CY2021Q4	us-gaap	Liabilities Liabilities	159228000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161871806
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161871806
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161012695
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161012695
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2754861000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2694646000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2327826000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2153576000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1365000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-192000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	425686000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	540894000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	602491000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	700122000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130714000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	131612000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380745000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	353387000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130714000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	131612000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380745000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	353387000
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2136000
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3688000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7753000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8399000
CY2021Q3	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	2994000
	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	8181000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81336000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58565000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	285837000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	172473000
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	78108000
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	81666000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	264688000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	290116000
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	161580000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	146913000
	us-gaap	Costs And Expenses CostsAndExpenses	558278000
	us-gaap	Costs And Expenses CostsAndExpenses	479169000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-30866000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15301000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-177533000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-125782000
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2295000
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	129000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2980000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	462000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2156000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	383000
	us-gaap	Share Based Compensation ShareBasedCompensation	53787000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1999000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	706000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26415000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14789000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-172554000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-124614000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	768000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-332000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1696000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	162000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-27183000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14457000
	us-gaap	Net Income Loss NetIncomeLoss	-174250000
	us-gaap	Net Income Loss NetIncomeLoss	-124776000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	161852
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	161852
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	160663
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160663
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	161580
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	161580
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	159651
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	159651
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-27183000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14457000
	us-gaap	Net Income Loss NetIncomeLoss	-174250000
	us-gaap	Net Income Loss NetIncomeLoss	-124776000
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-527000
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-41000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1187000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-43000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27704000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14495000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-175423000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-124813000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1766000
	us-gaap	Share Based Compensation ShareBasedCompensation	50735000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	642000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1108000
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1998000
	us-gaap	Gain Loss On Investments GainLossOnInvestments	706000
	us-gaap	Depreciation Depreciation	1537000
	us-gaap	Depreciation Depreciation	1701000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8633000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12449000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-575000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-1063000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2105000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4427000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-899000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1072000
	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-4845000
	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-4794000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	48000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-11000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3132000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-771000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	17771000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17260000
	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5959000
	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-4044000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-568000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-357000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90181000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-102540000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	269626000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	453847000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	360615000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	312317000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1121000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	90989000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142651000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6585000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13797000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6585000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13797000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7407000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-231388000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	160612000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	434848000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100410000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	564838000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	540894000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627009000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	425686000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	566955000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	425686000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	566955000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154842000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	326028000
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94640000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	160612000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100410000
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4234000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21652000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18569000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18312000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15546000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	53787000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50735000
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1610000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1114000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	373271000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6767000
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5992000
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6217000
CY2022Q3	us-gaap	Inventory Net InventoryNet	11836000
CY2021Q4	us-gaap	Inventory Net InventoryNet	14098000
CY2022Q3	acad	Short Term Inventory ShortTermInventory	5844000
CY2021Q4	acad	Short Term Inventory ShortTermInventory	7881000
CY2022Q3	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	5992000
CY2021Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	6217000
CY2022Q3	us-gaap	Inventory Net InventoryNet	11836000
CY2021Q4	us-gaap	Inventory Net InventoryNet	14098000
CY2022Q3	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	43490000
CY2021Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	27270000
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28794000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	25896000
CY2022Q3	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	11601000
CY2021Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	15717000
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10926000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9319000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9231000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8304000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2520000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2686000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	106562000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89192000
CY2022Q3	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	283128000
CY2022Q3	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	29000
CY2022Q3	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	1420000
CY2022Q3	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	281737000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	373475000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	9000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	213000
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	47
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	39
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	258250000
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1420000
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	258250000
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1420000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	290997000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	213000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	290997000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	213000
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	421986000
CY2022Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	989000
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	499785000
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	603000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	603000
	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Vesting Of Awards FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVestingOfAwards	1545000
	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Forfeited FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseForfeited	-104000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1055000
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	989000
CY2021Q4	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	15100000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4400000
CY2022Q3	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	12100000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2200000
CY2022Q3	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Recorded FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseRecorded	300000
	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Recorded FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseRecorded	400000
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 1.3 years to 8.7 years, some of which include options to extend for up to two five-year terms.
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	63000000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	64430000
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	some of which include options to extend for up to two five-year terms.
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2128000
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2014000
	us-gaap	Operating Lease Cost OperatingLeaseCost	5976000
	us-gaap	Operating Lease Cost OperatingLeaseCost	7016000
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2294000
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1713000
	us-gaap	Operating Lease Payments OperatingLeasePayments	6722000
	us-gaap	Operating Lease Payments OperatingLeasePayments	3423000
CY2022Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	880000
CY2021Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	166000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3201000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17543000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9231000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8304000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53769000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56126000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2354000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9563000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8892000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8971000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8336000
CY2022Q3	acad	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	36790000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	74906000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11906000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	63000000
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2020Q3	acad	Capitalization Of Right Of Use Asset CapitalizationOfRightOfUseAsset	40300000
CY2020Q3	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	40300000
CY2022Q3	acad	Capitalization Of Right Of Use Asset CapitalizationOfRightOfUseAsset	19200000
CY2022Q3	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	19200000

Files In Submission

Name	View Source	Status
0000950170-22-021438-index-headers.html	Edgar Link	pending
0000950170-22-021438-index.html	Edgar Link	pending
0000950170-22-021438.txt	Edgar Link	pending
0000950170-22-021438-xbrl.zip	Edgar Link	pending
acad-20220930.htm	Edgar Link	pending
acad-20220930.xsd	Edgar Link	pending
acad-ex10_1.htm	Edgar Link	pending
acad-ex10_2.htm	Edgar Link	pending
acad-ex10_3.htm	Edgar Link	pending
acad-ex31_1.htm	Edgar Link	pending
acad-ex31_2.htm	Edgar Link	pending
acad-ex32_1.htm	Edgar Link	pending
acad-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
acad-20220930_cal.xml	Edgar Link	unprocessable
acad-20220930_pre.xml	Edgar Link	unprocessable
acad-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
acad-20220930_def.xml	Edgar Link	unprocessable
acad-20220930_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

2022 Q4 Form 10-Q Financial Statement

#000095017022021438 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD ACADIA PHARMACEUTICALS INC Stock $acad

2022 Q4 Form 10-Q Financial Statement

#000095017022021438 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad